Twitter | Search | |
Search Refresh
Andrew Buelt Jun 13
Replying to @AndrewBuelt
And if you were taking a PPI then - 258 and 120
Reply Retweet Like
dr hanady manasfi Apr 8
TRAPS study : vs in high risk patients with syndrome
Reply Retweet Like
Davide Capodanno Apr 9
2.5 mg bid for stable atherosclerosis. Quite clear for PAD patients. For CAD the question is: to whom, to optimize risk/benefit? A) Any CAD patient based on COMPASS i/e criteria B) Those with both CAD and PAD C) CAD with prior events D) Subsets, such as DM or CKD
Reply Retweet Like
Joseph Shatzel May 13
Is this why rivaroxaban has comparatively more bleeding and breakthrough then apixaban?
Reply Retweet Like
Nathan Connell Dec 4
Great presentation of the CASSINI data for prophylaxis in high-risk ambulatory patients. Congratulations !
Reply Retweet Like
Saskia Middeldorp Dec 4
Cassini study primary prevention in high risk cancer pts by . Reducing the NNT to 26, but still many cases with not prevented.
Reply Retweet Like
Lissa Sugeng Mar 16
So is it safe to discontinue AC after Afib?- Still Don’t Know😕 Have to wait for OCEAN Trial after ablation RCT v John Day reminded us on Shared Decision Making
Reply Retweet Like
Michael Makris Mar 17
Prospective study of 66 patients. Fixed 2000u of 4-factor in patients with major bleeding on or . Effectiveness: good (65%) or moderate (20%). 30 day safety: thrombosis (8%) and death (14%).
Reply Retweet Like
Tania Ahuja Mar 16
in cancer associated ⤵️ 🔜 waiting for published results, but may take the 👑 here too based on safety data from 🤔 generally agree but think there may be a role for in renal dysfunction and in morbid obesity
Reply Retweet Like
Saskia Middeldorp Dec 2
Absolutely. Check the slides, one pt on 10 mg.
Reply Retweet Like
Mary Cushman MD Dec 4
Congrats to and colleagues on the CASSINI trial presented at today! lowering incidence in cancer patients at risk. Thanks for this work!
Reply Retweet Like
Tania Ahuja Mar 17
that’s 🔥 : home treatment of LOW risk PE with 💊 Exclusions: ❌ RV dysfunction, free floating thrombi ❌ hemodynamic instability ❌ need for parenteral analgesics or oxygen ❌ ‘serious’ comorbidity ❌ lack of compliance or support from family
Reply Retweet Like
Dr. Alex M. Benevides Jan 20
2.5mg2x/d+aspirin or rivaroxaban 5mg2x/d alone vs aspirin alone did not reduce graft failure in pts w/ recent , but: rivaroxaban 2.5mg2x/d+aspirin>>similar reductions in , as observed in
Reply Retweet Like
Michael Makris Dec 30
Evaluated across all indications, 15 or 20mg daily was associated with a higher rate of intracranial hemorrhage () compared to whilst 5mg bd was not. Fig 1 is the key. I do not think this is the end of this story.
Reply Retweet Like
Pierre Gholam Apr 10
Dr. Senzolo: don’t correct coagulation prophylactically and avoid fluid overload in bleeding cirrhotics. Also, some data to suggest may lower PHTN
Reply Retweet Like
JAMA Neurology Dec 15
A meta-analysis comprising 5 comparing to showed rivaroxaban 15-20mg daily increased risk of intracranial hemorrhage, while daily and twice daily did not. Learn more
Reply Retweet Like
EM/CCC Dec 5
Study finds risk of for highest w/ lowest w/ (rivarox > > > apixaban). Concurrent lowers risk for all agents by ~30-50% (risk still highest w/ rivarox, lowest w/ apix).
Reply Retweet Like
DocWire News May 3
Reply Retweet Like
Cardiology Today Jan 28
Ian DelConde, MD: The field of antithrombotic therapy in was reborn after the trial of ; results with other anticoagulants have not been as strong in this population, so rivaroxaban may be a "Goldilocks drug."
Reply Retweet Like
Arie Blitz, MD, MBA Jan 17
Reply Retweet Like